格隆汇9月11日｜今日港股创新药板块经历惊险深V行情，翰森制药、百济神州、石药集团分别跌 7.98%、7.44%和6.86%，恒生医药ETF(159892)盘中一度深跌6.49%，随后跌幅快速收窄至-3.3%，盘中 涌现资金净申购9200万份，港股通医疗ETF从最深4.64%跌幅收窄至-1.88%。 消息面上，9月10日《纽约时报》报道，特朗普政府正在考虑通过一项行政命令草案，计划对来自中国 的创新药（尤其是实验性药物）实施更严格的限制。 值得关注的产品，及截至发稿涨跌幅： 全球医药全产业链代表：恒生医药ETF(159892)，-3.3%，前十大权重股涵盖多只创新高的药企：百济神 州、药明生物、康方生物、中国生物制药、三生制药。 CXO与AI医疗的深度聚焦：港股通医疗ETF(520510)，-1.88%，指数CXO浓度全市场领先，权重股包括 药明生物（CDMO冠军）：（双抗药物研发全球领跑者）、微创医疗（心血管介入领域国产替代先 锋）、京东健康（医疗数字化领跑者）。 ①华泰证券指出，2025年以来（截至8月27日），全球创新药达成BD 交易数量540 项，披露总金额达 1634.10 亿美元，其中国产创新药达 ...

Group 1 - The Hang Seng Index rose over 1% during the trading session, reaching a peak of 26,296.6 points, marking a nearly four-year high following the previous day's performance [1] - Other key indices in the Hong Kong stock market also saw collective gains, with the Hang Seng Tech Index increasing nearly 2% and the Hang Seng China Enterprises Index rising over 1% [1] - Southbound capital has seen a continuous net inflow for eight consecutive days, with a cumulative net purchase amount reaching a record high of 10,389.4 million HKD year-to-date [1] Group 2 - Recent trends indicate that Southbound capital is primarily flowing into sectors such as retail, automotive, consumer services, non-ferrous metals, and pharmaceuticals [1] - Changjiang Securities noted that the sustained inflow of Southbound capital is enhancing marginal pricing power, and if domestic low-interest rates persist alongside rising weights in the ERP model, more funds may be allocated to the Hong Kong stock market [1] - The potential for further increases in the Hong Kong stock market is supported by the transmission from broad monetary policy to broad credit, along with possible interest rate cuts in the U.S. that could improve global liquidity, as well as performance realization in the AI industry [1] Group 3 - Relevant ETFs include the Hang Seng Tech Index ETF (513180), which focuses on leading technology AI companies, new energy vehicle manufacturers, and chipmakers [2] - The Hang Seng Internet ETF (513330) targets leading internet companies in Hong Kong, benefiting from reduced competition [2] - The Hong Kong Stock Connect Medical ETF (520510) has a leading CXO content among all market ETFs and is expected to take over the innovation drug main line [2]